BlackRock
KRTX

BlackRock’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

BlackRock’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,015,374
Closed -$638M – 5431
2023
Q4 		$638M Buy
2,015,374
+52,457
+3% +$10.2M 0.02% 816
2023
Q3 		$332M Buy
1,962,917
+98,281
+5% +$18.5M 0.01% 1197
2023
Q2 		$404M Sell
1,864,636
-605,163
-25% -$130M 0.01% 1093
2023
Q1 		$449M Buy
2,469,799
+66,068
+3% +$12.6M 0.01% 984
2022
Q4 		$472M Buy
2,403,731
+146,037
+6% +$31.3M 0.01% 922
2022
Q3 		$508M Buy
2,257,694
+371,050
+20% +$75.1M 0.02% 807
2022
Q2 		$239M Buy
1,886,644
+260,239
+16% +$29.9M 0.01% 1392
2022
Q1 		$206M Sell
1,626,405
-12,212
-0.7% -$1.37M 0.01% 1655
2021
Q4 		$215M Buy
1,638,617
+55,120
+3% +$7.12M 0.01% 1687
2021
Q3 		$194M Buy
1,583,497
+3,780
+0.2% +$436K 0.01% 1740
2021
Q2 		$180M Buy
1,579,717
+179,462
+13% +$21M 0.01% 1843
2021
Q1 		$168M Buy
1,400,255
+26,543
+2% +$3.01M ﹤0.01% 1843
2020
Q4 		$140M Buy
1,373,712
+86,154
+7% +$7.98M ﹤0.01% 1862
2020
Q3 		$99.6M Buy
1,287,558
+27,853
+2% +$2.37M ﹤0.01% 1885
2020
Q2 		$140M Buy
1,259,705
+319,129
+34% +$27.7M 0.01% 1609
2020
Q1 		$67.7M Buy
940,576
+320,218
+52% +$27.4M ﹤0.01% 1889
2019
Q4 		$46.7M Buy
620,358
+346,576
+127% +$15.2M ﹤0.01% 2409
2019
Q3 		$4.47M Buy
+273,782
New +$5.32M ﹤0.01% 3517

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

BlackRock's KRTX Position: Q1 2024 in Review

BlackRock sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 2,015,374 shares — an estimated $638M sold.

BlackRock first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $638M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • BlackRock reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 2,015,374 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $638M.
  • BlackRock first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • BlackRock's Karuna Therapeutics, Inc. Common Stock position peaked at $638M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.